Georgiadis: “We welcome Samsung Bioepis to Greece” – What it means for patients
Greece’s Health Minister welcomed Samsung Bioepis’ presence in the Greek market through its strategic partnership with Pharmachim, putting the potential benefit for patients at the center of his message. The biosimilar portfolio spans major therapeutic areas from oncology and hematology to ophthalmology and nephrology, while wider biosimilar use can expand access to biological therapies and help health systems use available resources more efficiently.
